Everything below concerns purity testing. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-29. Numbers and descriptions here follow the published literature rather than marketing material.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Lynch, Britt-Gibson, and Black all initially auditioned for the role of Alamo before being assigned their parts. Rosalía's song "Malamente" had appeared in season 1 episode five "'03 Bonnie and Clyde, and she co-wrote "Lo Vas a Olvidar" with Billie Eilish for the 2021 special episode "Fuck Anyone Who's Not a Sea Blob". Hardison previously worked with Zendaya on her Disney Channel series K.C. Undercover, playing her character's father, Craig Cooper. In October, Colleen Camp, Gideon Adlon, Hemky Madera, Homer Gere, Jack Topalian, Jessica Blair Herman, Madison Thompson, Matthew Willig, Rebecca Pidgeon, and Sam Trammell joined the cast in more recurring roles.
=== Tentoxin === Tentoxin is most commonly known as a naturally occurring phytotoxic cyclic tetra-peptide that is excreted by fungi of the Alternaria alternata family. There were four total syntheses of tentoxin that were published to this day that gave very poor total yields. These poor yields were mainly due to the introduction of the dehydro amino acid, more specifically the cyclization step. There was a method developed in order to stereospecifically introduce Z-dehydrophenylalanine by a modified Erlenmeyer adolization reaction. An aldol reaction is a transformation that is due to the dimerization of an aldehyde (or ketone) to a beta-hydroxy aldehyde (or ketone) by alpha C-H addition of one reactant molecule to the carbonyl group of a second reactant molecule. This reaction requires at least one of the reactants to have hydrogens. The precursor of tentoxin, the linear tetrapeptide (Boc-R1Ala-Leu-R2ΔZPhe-Gly-OMe), was obtained from Boc-Leu-Gly-OH with a 72% yield. This linear tetrapeptide with carbon-14 was utilized to study the four cyclization reagents, DPPA, DCC-PfpOH, HBTU, and HATU. By doing so, this gave the tentoxin an 81% cyclization yield.
=== Major depressive disorder === The mechanistic rationale for KOR antagonism in major depressive disorder (MDD) derives from the observation that chronic stress and depression are associated with higher activity of the KOR system. KOR activation suppresses dopamine release and prevents dopamine rebound after stress exposure, thereby leading to anhedonia and depressive phenotypes. KOR antagonists reverse this pathway by disinhibiting dopaminergic tone and restoring reward sensitivity. KOR-mediated upregulation of pro-inflammatory signaling in microglia likely drives the depression pathophysiology, and antagonism may provide benefits. The claustrum-prelimbic cortex circuit operates via dynorphin and KOR signaling to modulate cognitive and affective functions. Buprenorphine/samidorphan (ALKS-5461) displayed antidepressant efficacy in randomized controlled trials as an adjunctive therapy and has shown durable effects with a favorable safety profile including low abuse potential and minimal withdrawal symptoms. A phase 2 study demonstrated significant reduction of depressive symptoms and improvement in anhedonia when aticaprant was added to existing antidepressant therapy. A phase 3 clinical trials (KOASTAL-1 and additional studies) of navacaprant failed to achieve statistically significant superiority over placebo across the broader MDD population, with its development discontinued for this purpose in early 2025.
The origin of the modern smallpox vaccine has long been unclear, but horsepox was identified in the 2010s as the most likely ancestor. Edward Jenner had obtained his vaccine from a cow, so he named the virus vaccinia, after the Latin word for cow. Jenner believed that both cowpox and smallpox were viruses that originated in the horse and passed to the cow, and some doctors followed his reasoning by inoculating their patients directly with horsepox. The situation was further muddied when Louis Pasteur developed techniques for creating vaccines in the laboratory in the late 19th century. As medical researchers subjected viruses to serial passage, inadequate recordkeeping resulted in the creation of laboratory strains with unclear origins. By the late 19th century, it was unknown whether the vaccine originated from cowpox, horsepox, or an attenuated strain of smallpox. In 1939, Allan Watt Downie showed that the vaccinia virus was serologically distinct from the "spontaneous" cowpox virus. This work established vaccinia and cowpox as two separate viral species. The term vaccinia now refers only to the smallpox vaccine, while cowpox no longer has a Latin name. The development of whole genome sequencing in the 1990s made it possible to compare orthopoxvirus genomes and identify their relationships with each other. The horsepox virus was sequenced in 2006 and found to be most closely related to vaccinia. In a phylogenetic tree of the orthopoxviruses, horsepox forms a clade with vaccinia strains, and cowpox strains form a different clade.
Sources: en.wikipedia.org
Although the preponderance of evidence is on the side of a multidimensional measure, the issue has not been fully resolved owing in part to limitations in the methodological knowledge available on distinguishing between substantive and method variance.
However, a 2021 study on the decay chains of flerovium isotopes suggests that there is no strong stabilizing effect from Z = 114 in the region of known nuclei (N = 174), and that extra stability would be predominantly a consequence of the neutron shell closure. Although known nuclei still fall several neutrons short of N = 184 where maximum stability is expected (the most neutron-rich confirmed nuclei, 293Lv and 294Ts, only reach N = 177), and the exact location of the center of the island remains unknown, the trend of increasing stability closer to N = 184 has been demonstrated. For example, the isotope 285Cn, with eight more neutrons than 277Cn, has a half-life almost five orders of magnitude longer. This trend is expected to continue into unknown heavier isotopes in the vicinity of the shell closure.
== Career == From 1988 to 1989, Brayden worked as a research assistant at the University of Cambridge. He undertook a postdoctoral fellowship at Stanford University in 1989. In 2001, he joined UCD as an assistant professor and was promoted to associate professor in 2005, to professor in 2006, and to full professor in 2014. Between 2003 and 2006, Brayden was the co-founding chairperson of the UK–Ireland Chapter of the Controlled Release Society. He was employed as the Deputy Coordinator of an EU 7th Framework grant on oral nanomedicines, TRANS-INT. He holds the role of Co-lead principal Investigator at CÚRAM, the Research Ireland Centre for Medical Devices, and is the coordinator of the Horizon Europe Consortium, BUCCAL-PEP. He is the Field Chief Editor of Frontiers in Drug Delivery. Brayden was appointed to Ireland's National Research Ethics Committee for Clinical Trials by the Minister for Health in 2021, and in 2024 became chairperson of NREC-CT D. In 2026, he received the higher doctorate of Doctor of Science (DSc) from the National University of Ireland on the basis of his published work in pharmacology.
== Description == N. christyi is a medium to moderately long, somewhat compressed, moderately slender-bodied, but heavily built snake, with a medium length tapering tail. The head is short, with an indistinct canthus, and is distinct from the neck. The neck is capable of being spread into a hood. The eyes are relatively small in size with round pupils. The dorsal scales are smooth and shiny. The average total length (including tail) of an adult specimen is around 1.1 metres (3.6 ft), but it may grow to upwards of 2.3 metres (7.5 ft) The rostral is once and a half as broad as deep, and is just visible from above. The internasals are as long as the prefrontals, and are extensively in contact with the preocular. The frontal is small, not longer than broad, broadest behind, forming very open angles in front and behind, not quite as long as its distance from the rostral, half as long as the parietals. The supraocular is much narrower than the frontal. The posterior nasal is in contact with the single preocular. There are two or three postoculars. The temporals are 2+2 or 2+3. There are seven upper labials, the third and fourth entering the eye, the fourth and fifth in contact with the lower postocular. There are four lower labials in contact with the anterior chin shields. The posterior chin shields are narrower and a little shorter than the anterior chin shields and separated by one scale. The dorsal scales are in 19 rows on the neck, and in 17 rows at midbody. The ventrals number 221. The anal is entire. The subcaudals number 70. Colouration is blackish brown above.
The complement component C5 can be also activated by fluid phase C5 convertase. C5 is activated by CVFBb in the presence of complement component C6 and the C5b6 complex is formed. However, when C6 is added after C5 has been converted to C5b, the C5b6 complex fails to form. Therefore, the activation of C5 results in a transient binding site for C6. Hydrophobic sites are probably exposed upon C5 activation because C5b undergoes aggregation when C5 is converted to C5b in the absence of C6. Interactions between C5 and C6 or C5 and membranes are noncovalent. (In contrast, it is the labile thiol ester that permits covalent attachment between C3 and nucleophilic acceptors.) The proteolytic cleavage of C5 is the only known enzymatic event in assembly of the cytolytic membrane attack complex of complement. Once bound, C5 is exceptionally efficient in producing hemolysis, requiring less than seven specifically bound molecules per cell for the production of a hemolytic lesion. The extent of formation of the C5 intermediate complex is primarily dependent on the number of molecules of C4, C2 and C3 present on the cells employed for its generation. In these respects, the mode of action of C5 is completely analogous to that of the other components of complement. The C5 step differs, however, in other aspects. The binding of C5 is influenced by C6 and C7, components which are thought to act subsequent to it in the complement sequence. In addition, the hemolytic activity of the isolated C5 intermediate complex is exceedingly labile, having an average half-life at 30 °C of only 9 min.
Sources: en.wikipedia.org
The effects of drugs displacing each other and changing the clinical effect (though important in some examples) is vastly overestimated usually and a common example incorrectly used to display the importance of this effect is the anticoagulant warfarin. Warfarin is highly protein-bound (>95%) and has a low therapeutic index. Since a low therapeutic index indicates that there is a high risk of toxicity when using the drug, any potential increases in warfarin concentration could be very dangerous and lead to hemorrhage. In horses, it is very true that if warfarin and phenylbutazone are administered concurrently, the horse can develop bleeding issues which can be fatal. This is often explained as being due to the effect of phenylbutazone ejecting warfarin from its plasma protein, thus increasing the concentration of free warfarin and increasing its anticoagulant effect. However, the real problem is that phenylbutazone interferes with the liver's ability to metabolize warfarin so free warfarin cannot be metabolized properly or excreted. This leads to an increase in free warfarin and the resulting bleeding problems.
The drugs are administered sequentially rather than together for practical and ethical reasons. A mixture could cause the drugs to precipitate from solution, thereby reducing drug delivery and risking pain due to vascular blockage. The potassium chloride, in particular, would cause severe pain as it travels through the bloodstream and distress as it acts upon the heart, were the person not first rendered fully unconscious. The intravenous tubing leads to a room next to the execution chamber, usually separated from the condemned by a curtain or wall. Typically, a prison employee trained in venipuncture inserts the needle, while a second prison employee orders, prepares, and loads the drugs into the lethal injection syringes. Two other staff members take each of the three syringes and secure them into the IVs. After the curtain is opened to allow the witnesses to see inside the chamber, the condemned person is then permitted to make a final statement. Following this, the warden signals that the execution may commence, and the executioner(s) (either prison staff or private citizens depending on the jurisdiction) then manually inject the three drugs in sequence. During the execution, the condemned's cardiac rhythm is monitored. Death is pronounced after cardiac activity stops. Death usually occurs within seven minutes; however, due to complications in finding a suitable vein, the entire procedure can take up to two hours, as was the case with the execution of Christopher Newton on May 24, 2007.
==== Italy ==== Cider was once widely produced in northern Italy's apple growing regions, with a marked decline during fascist rule, due to the introduction of a law banning the industrial production of alcoholic beverages derived from fruits of less than 7% ABV, which was aimed at protecting wine producers. Present laws and regulations are favourable to cider makers, but production has only survived in a few alpine locations, mostly in the regions of Trentino, and in Piedmont, where it is known as vin ëd pom (apple wine) or pomada, because it traditionally was left to ferment in a vat along with grape pomace, giving it a distinctive reddish colour.
The youth set-up did not replicate the success of the late 1990s and early 2000s, though Arsenal consistently finished fourth or higher in the league between 2006 and 2011. The club earnt a reputation of functioning as a "feeder club" to bigger teams, as Wenger struggled to keep hold of his best players. He described this period as "very sensitive" because of the financial restrictions that came with the stadium move. Since the 2011–12 season, Wenger has reverted to buying proven talent, and blended experience with youth in domestic cup competitions. Arsenal have benefited from increased revenue since the Emirates move, and negotiating new sponsorship deals has allowed Wenger to make marquee signings such as Özil, Sánchez, Granit Xhaka, Alexandre Lacazette and Pierre-Emerick Aubameyang. Observing Wenger's transfer policy in 2009, Sir Alex Ferguson commented that it lacked balance and needed defensive players to solidify the Arsenal team. The players Wenger recruits have often been criticised for their character and leadership capabilities; footballer Joey Barton suggested it was because the manager discouraged them from commanding: "Sometimes you need someone to galvanise and that might be a shouter and bawler. It may not be Arsene's way, but I think they lack that." Wenger is perceived as frugal given his inactivity in transfer windows, but he has denied the stereotype: "Of course people say always to buy but you cannot make careers [and you cannot] buy every time you have an injured player. You know I have the wrong reputation. I'm not scared to spend money.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.